<DOC>
	<DOCNO>NCT00894894</DOCNO>
	<brief_summary>Multicenter , open-label , dose-ranging study two part : maximum tolerate dose ( MTD ) segment ( first 28-day course MP 470 ) follow long-term safety segment . MTD segment : follow standard oncology phase-I design ; within-patient dose level adjustment prohibit ; patient participate one three stage : 1 . Accelerated Titration Stage 2 . Dose Escalation/De-Escalation Stage 3 . Dose Confirmation Stage</brief_summary>
	<brief_title>Safety Study Determine Maximum Tolerated Dose , Pharmacokinetics Pharmacodynamics Oral MP470 , Multitargeted Tyrosine Kinase Inhibitor , Patients With Solid Malignancies</brief_title>
	<detailed_description>Multicenter , open-label , dose-ranging study two part : MTD Segment ( first 28-day course MP 470 ) follow Long-Term Safety Segment MTD Segment : follow standard oncology phase-I design ; within-patient dose level adjustment prohibit ; patient participate one three stage : Accelerated Titration Stage : 1 patient per dose level ; first patient receive MP 470 100 mg/day ; subsequent patient assign high dose level base modify Fibonacci sequence ; stage stop first-course DLT observe grade-2 great MP 470-related toxicity observe 2 dose level ; dose next patient prohibit previous patient 's MTD-Segment result confirm Dose Escalation/De-Escalation Stage : 3 patient per cohort ; two additional patient enrol receive last dose level study Accelerated Titration Stage ( first 3-patient cohort ) ; subsequent 3-patient cohort assign dose level conditional number patient first-course DLT previous cohort ; new cohort enrol MTD define ; dose next cohort prohibit previous cohort 's MTD-Segment result confirm Dose Confirmation Stage : additional 6-10 patient enrol receive MP 470 establish MTD ; patient accrual stop follow Dose Confirmation Long-Term Safety Segment : patient continue receive 28-day course MP 470 experience unmanageable toxicity disease progression ; within-patient dose level adjustment base toxicity ; DLT precede 28-day course mandate one-level dose reduction ; one-level dose increase possible absence grade-3 great MP 470-related AEs precede 28-day course</detailed_description>
	<criteria>1 . The patient histological cytological diagnosis unresectable metastatic solidtumor cancer refractory standard therapy standard therapy exists . Patients refractory lymphoma ( Hodgkin 's NHL ) also permit participate . 2 . The patient must read , understand sign IRBapproved inform consent form ( ICF ) confirm willingness participate trial . 3 . The patient willing able participate require evaluation procedure describe study protocol , include swallow MP 470 capsule . 4 . The patient least 18 year old . 5 . The patient capable fast 6 hour . 6 . The patient Karnofsky Performance Status ≥ 70 ( see Appendix 5 ) . 7 . The patient adequate bone marrow function evidence , minimum , Hgb ≥ 9 g/dL , ANC ≥ 1.5 x 109/L platelet count ≥ 100 x 109/L . 8 . The patient normal renal hepatic function evidence , minimum , total serum bilirubin ≤ 2 mg/dL ; AST ALT ≤ 2.5 x ULN ( upper limit normal clinical laboratory ) , ≤ 5 x ULN acceptable due hepatic metastasis ; serum albumin ≥ 2 g/dL ; serum creatinine ≤ 2 mg/dL . 9 . The patient normal cardiac function opinion investigator support leave ventricular ejection fraction ( LVEF ) 50 % great screen echocardiogram , significant abnormality screen ECG ( eg , leave bundle branch block , III degree AV block , acute myocardial infarction QTc interval &gt; 450 msec ) history additional risk factor torsade de pointes ( eg , heart failure , hypokalemia family history Long QT Syndrome ) . 10 . The patient recuperate prior surgical procedure include least 4 week rest since major surgery . 11 . The patient childbearing potential negative serum pregnancy test within past 14 day . 12 . The patient reproductive potential agree use use approve method contraception study 3 month follow last dose MP 470 . 13 . The patient lactating . 1 . The patient lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise patient 's safety , interfere absorption metabolism oral MP 470 , put study outcome risk . 2 . The patient serious , uncontrolled active infection require systemic treatment . 3 . The patient history significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure and/or myocardial infarction . 4 . The patient receive anticancer agent ( ) within past 3 week , include investigational agent , chemotherapy ( 6 week nitrosoureas mitomycin ) , immunotherapy , biologic hormonal therapy LHRH agonist . 5 . The patient receive radiation therapy within past 4 week . 6 . The patient grade2 severe toxicity ( alopecia ) continue prior anticancer therapy . 7 . The patient active CNS metastasis ( primary brain tumor permit ) . 8 . The patient require treatment immunosuppressive agent corticosteroid stable dos least 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>MP470</keyword>
	<keyword>MP-470</keyword>
	<keyword>SuperGen</keyword>
	<keyword>Tyrosine</keyword>
	<keyword>Kinase</keyword>
	<keyword>Inhibitor</keyword>
	<keyword>Solid Malignancies</keyword>
	<keyword>Oncology</keyword>
</DOC>